Zinaida Good
Also known as: Zinaida Tebaykina, Zina Good
Stanford University, Genentech Inc, University of British Columbia
Research areas: Medicine · Oncology · CAR-T cell therapy research · T-cell and B-cell Immunology · Immunotherapy and Immune Responses
0000-0003-2343-5771
About
Zinaida Good, Ph.D., is an Assistant Professor of Medicine in the Division of Immunology and Rheumatology and the Center for Biomedical Informatics Research at the Stanford University School of Medicine and the Director of the Cancer Cell Therapy Data Hub at the Stanford Center for Cancer Cell Therapy. Her research program focuses on understanding and enhancing engineered T cell immunotherapies for cancer and immune-mediated diseases through innovative computational approaches and systems immunology. During her postdoctoral training with Drs. Crystal Mackall and Sylvia Plevritis, Dr. Good performed fate mapping studies to identify features of optimal CAR T cells in large B cell lymphoma (LBCL) and diffuse midline glioma (DMG), and discovered the role of CAR T regulatory cells in resistance to CD19-CAR in LBCL. She earned her Ph.D. in Computational & Systems Immunology from Stanford University, where she trained with Drs. Garry Nolan and Sean Bendall and developed methods to build and leverage lymphocyte differentiation trajectories in health and cancer. Dr. Good's background in experimental immunology and oncology combines two years of experience in Discovery Oncology at Genentech with B.S. and M.S. degrees in Microbiology & Immunology from the University of British Columbia, where she investigated mechanisms of T cell memory with Dr. Michael Gold. Dr. Good’s work includes 4 first-author papers (Nature Medicine 2018 & 2022, Nature Biotechnology 2019, Trends in Immunology 2019), 18+ co-authored papers (including Nature 2019, 2022, 2024, Science 2021, Nature Methods 2016, 2022, and NEJM 2024), and a multinational patent. Her research is supported by the NIH Pathway to Independence Award, Parker Institute for Cancer Immunotherapy Bridge Fellowship, American Cancer Society Institutional Research Grant, and Parker Institute for Cancer Immunotherapy Innovation Challenge Grant. Dr. Good has been named an Arthur & Sandra Irving Cancer Immunology Fellow in 2022 and an AACR-Woman in Cancer Research Scholar in 2024.
Employment
-
Stanford University Assistant Professor2025 - Present
-
Stanford University Instructor2023 - 2024
-
Stanford University Postdoctoral Fellow2018 - 2023
-
Stanford University Ph.D. Student2013 - 2018
-
Genentech Inc Research Associate2013 - 2013
-
Genentech Inc Contractor Research Associate2012 - 2013
-
Genentech Inc Intern2011 - 2012
-
The University of British Columbia M.S. Student2008 - 2011
-
Genentech Inc Intern2007 - 2007
- 2006 - 2006
-
University of British Columbia Laboratory Assistant2005 - 2005
Education
-
Stanford University Doctor of Philosophy2013 - 2018
-
University of British Columbia Master of Science2008 - 2012
-
University of British Columbia Bachelor of Science2003 - 2008
Projects & Funding
-
10X Genomics / PICI Pilot Project Support Parker Institute for Cancer Immunotherapy2022 - 2023
-
Stanford Cancer Institute Fellowship Stanford Cancer Institute2020 - 2021
-
2020-08-01 to 2021-07-31 | NIH-U54 Pilot Project Grant Stanford Center for Cancer Systems Biology2020 - 2021
-
Directing T-lymphocyte fate specification choices in cancer immunotherapy applications Parker Institute for Cancer Immunotherapy2018 - 2020
Publications (31)
- Clonal hematopoiesis and cytopenias following CAR19 therapy Save
- In vivo genome-wide CRISPR screens of human T cells in solid tumours. Save
- CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer Save
- Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering Save
- Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Save
- Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results. Save
- Regulatory T cell therapies: from patient data to biological insights. Save
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias Save
- CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Save
- Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL. Save
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Save
- Engineered CD47 protects T cells for enhanced antitumour immunity. Save
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Save
- Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium Save
- Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy Save
- Advancing T cell-based cancer therapy with single-cell technologies. Save
- Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA Save
- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Save
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling Save
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET Save